Breaking News, Collaborations & Alliances

AB2 Bio and WuXi Biologics Enter Collaboration

Set-up and accelerate commercial-scale manufacturing of Tadekinig alfa.

By: Contract Pharma

Contract Pharma Staff

AB2 Bio Ltd., a Swiss advanced clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, and WuXi Biologics, a global company with open-access biologics technology platforms, have entered into a collaboration to set-up and accelerate commercial-scale manufacturing of Tadekinig alfa, AB2 Bio’s novel recombinant IL-18 binding protein.   Per the agreement, AB2 Bio is in the process of transferring manufacturing of Tadekinig alfa t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters